Table 3.
Baseline characteristics of included rheumatologists and patients
| Characteristic | Results |
|---|---|
| Rheumatologists (n=14) | |
| Age, in years* | 45.2 (39.5 to 56.7) |
| Female gender (%) | 46.2 |
| PhD degree or pursuing a PhD (%) | 69.2 |
| Experience as rheumatologist, in years* | 6.9 (3.6 to 19.9) |
| Patient contact per week* (%) | 60.0 (45.0 to 70.0) |
| Guideline knowledge† (0–10); (−5.2 to 10) | |
| General | 8.1 (1.0) |
| Specific | 6.2 (1.8) |
| Guideline agreement† (0–5) | |
| General | 4.8 (0.5) |
| Specific | 4.5 (0.5) |
| Outcome expectancy† (0–5) | 3.9 (0.8) |
| Cognitive bias† (0–22) | 12.5 (4.2) |
| Thinking styles† (0–100) | |
| Rational | 79.5 (9.2) |
| Experiential | 63.7 (7.5) |
| Numeracy† (0–7) | 6.6 (1.1) |
| Personality† (0–5) | |
| Extraversion | 3.4 (0.7) |
| Neuroticism | 2.8 (0.4) |
| Openness to experience | 3.7 (0.6) |
| Consciousness | 3.7 (0.4) |
| Agreeableness | 3.8 (0.3) |
| Patients (n=137) | |
| Age, in years† | 58.9 (14.1) |
| Female gender (%) | 67.2 |
| Disease duration, in years* | 0 (0 to 7) |
| RF and/or aCCP positive (%) | 85.4 |
| Erosions (%) | 38.3 |
| ESR* (mm/h) | 25 (12 to 36) |
| Comorbidity (%) | 66.4 |
| Number of available DMARD treatment options*‡ | 15 (14 to 15) |
*Median (IQR).
†Mean (SD).
‡Includes both conventional and biological DMARD treatment options.
aCCP, anti-cyclic citrullinated peptide antibody; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.